TOKYO -- Takeda Pharmaceutical will sell five prescription products to China's Hasten Biopharmaceutic in a $322 million deal as Japan's top drugmaker continues to slash debt from its acquisition of Ireland-based peer Shire.
The transaction is slated to close by the end of June and covers cardiovascular and metabolism treatments sold in mainland China, including the Ebrantil blood pressure reducer.
.JPG?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
